- Tags: IOLs
Products
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs
U.S. age indication now includes patients aged 21 to 60 years old, making nearly 8 million refractive patients eligible for implantable collamer lens implantation.
Products
BVI reports first US implantations of FINEVISION HP Trifocal IOL
Surgeon-led rollout includes five successful procedures across the country of the FDA-approved, presbyopia-correcting lens.
Research
Study: enVista Aspire IOL delivers expanded intermediate vision without sacrificing distance
Prospective study evaluates the enhanced monofocal IOL among patients undergoing standard phaco.Products
FDA approves BVI Medical's FINEVISION HP trifocal IOL
Third-generation premium lens features a unique diffractive design while utilizing the proprietary CoPODize technology for minimized visual disturbances.
Products
FDA approves Rayner's RayOne EMV Toric IOL
Newest lens offers high-quality visual outcomes for patients with astigmatism, including monofocal levels of contrast sensitivity, and low dysphotopsia.
Research
Pivotal study showcases enVista Envy IOL's full range of vision
Data includes meeting all efficacy and safety outcomes, with the lens demonstrating statistical superiority in visual outcomes and a favorable dysphotopsia profile.
Products
VirtuaLens launches with VR-based IOL simulator
New company debuts a first-of-its-kind, customizable VR simulator for patients to try out lenses ahead of surgery in immersive 3D lifestyle scenarios.
Research
Are blue light-filtering IOLs beneficial for AMD?
Blue light-filtering IOLs demonstrate no protective effect on the risk of developing exudative AMD.
Research
Researchers identify high-risk patients prone to IOL dislocation
Trauma, high myopia, and glaucoma may place patients at higher risk for intraocular lens dislocation.
Business
Alcon to acquire STAAR Surgical
The $1.5 billion deal includes STAAR’s FDA-approved implantable collamer lenses; expected to close within 6 to 12 months.
Research
New data finds increased prevalence of refractive surgery among cataract patients
Clinicians may need to consider new ways of calculating IOL power due to prevalence of high myopia and previous refractive surgery.
Pipeline
SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform
Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.
Products
Haag-Streit launches corneal map for the Lenstar 900
The optical biometer’s newest integratable feature enables simultaneous measurement of a wider range of biometric parameters for cataract surgery planning.
Pipeline
FDA OKs clinical trial on Atia Vision's novel IOL for cataract patients
IDE approval brings company one step closer toward seeking regulatory clearance for the OmniVu Lens System, a dual-optic IOL.
Research
SpyGlass Pharma reports positive 18-month data on glaucoma sustained delivery system
Presented at ASCRS, new findings show promising visual outcomes and IOP lowering following sustained-release delivery of bimatoprost.
Products
Alcon debuts new digital platform for clinics and surgery centers
Designed for use within the Alcon Vision Suite, this cloud-based platform connects clinics’ patient and surgery data to a surgery center.
Research
Clinical outcomes support JJV's violet-filtering IOL for glaucoma
New research on the Tecnis Symfony OptiBlue IOL shows promising visual outcomes just one week after implantation post-cataract surgery.
Products
B+L's enVista IOLs return to market after voluntary recall
Company announces conclusion of investigation into reported cases of TASS involving the enVista IOL product line.
Products
Alcon launches Clareon PanOptix Pro IOL in the US
With a broad commercial rollout planned for next month, this will be the company’s first presbyopia-correcting IOL available in its Clareon AutonoMe preloaded system.
Products